EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System

Abhishek Kandukuru, Priyanka Sharma, Sheeba Verghese Gupta, Augustine Nkembo, Vijaykumar Sutariya iD

Canadian Journal of Physiology and Pharmacology · 2024

DOI: 10.1139/cjpp-2024-0128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2024. Verfasst von Abhishek Kandukuru und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA, USA. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Norepinephrine–dopamine reputake inhibitors (NDRIs), including bupropion, methylphenidate, atomoxetine, and reboxetine, are commonly prescribed for psychiatric disorders such as narcolepsy, attention-deficit/hyperactivity disorder, and depression. Cardiovascular adverse events have been reported to the FDA despite their effectiveness. This pharmacovigilance study analyzed cardiovascular adverse events associated with NDRIs using the FDA Adverse Event Reporting System data from January 2004 to December 2021. A retrospective analysis of adverse event reports was conducted, employing time-trend analysis and disproportionality evaluation to assess cardiovascular risks. Bupropion had the greatest reported odds ratios (RORs) for tachycardia (ROR = 4.2, 95% CI: 4.0–4.4) and hypertension (ROR = 3.5, 95% CI: 3.3–3.7), while methylphenidate showed greater ROR for arrhythmias (ROR = 2.8, 95% CI: 2.6–3.0) and palpitations (ROR = 3.1, 95% CI: 2.9–3.3). Reboxetine had signals for palpitations (ROR = 3.0, 95% CI: 2.8–3.2) and myocardial infarction (ROR = 2.7, 95% CI: 2.5–2.9), whereas atomoxetine revealed signals for hypertension (ROR = 2.9, 95% CI: 2.7–3.1) and syncope (ROR = 2.5, 95% CI: 2.3–2.7). Time-trend analysis revealed temporal variability in the cardiovascular risks connected with NDRIs. Our research elucidates cardiovascular safety profiles for NDRIs, highlighting the necessity for continuous pharmacovigilance. The observed variations in adverse events emphasize the need for ongoing surveillance to mitigate potential cardiovascular risks and enhance patient safety and treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationCardiovascular DiseasesHumansUnited StatesAtomoxetine HydrochlorideReboxetineRetrospective StudiesBupropionDopamine Uptake InhibitorsMaleFemaleMethylphenidate

Stichwörter der Autor:innen

FAERSFDAcardiovascularnorepinephrine–dopamine reuptake inhibitorspharmacovigilance

Substanzen

Atomoxetine HydrochlorideReboxetineBupropionDopamine Uptake InhibitorsMethylphenidate

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA, USA.

ORCID-Profile: Vijaykumar Sutariya

Zitieren

APA

Kandukuru, A., Sharma, P., Verghese Gupta, S., Nkembo, A., & Sutariya, V. (2024). Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0128

Vancouver

Kandukuru A, Sharma P, Verghese Gupta S, Nkembo A, Sutariya V. Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Canadian Journal of Physiology and Pharmacology. 2024. doi:10.1139/cjpp-2024-0128

BibTeX
@article{Kandukuru2024,
  author = {Kandukuru, Abhishek and Sharma, Priyanka and Verghese Gupta, Sheeba and Nkembo, Augustine and Sutariya, Vijaykumar},
  title = {Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2024},
  doi = {10.1139/cjpp-2024-0128}
}
Kostenlos starten →